Rifaximin Attenuates Liver Fibrosis and Hepatocarcinogenesis in a Rat MASH Model by Suppressing the Gut–Liver Axis and Epiregulin–IL-8-Associated Angiogenesis
International Journal of Molecular Sciences · 2025
DOI: 10.3390/ijms26146710 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2025. Verfasst von Naoki Nishimura und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology, Nara Medical University, Kashihara 634-8521, Nara, Japan. Hauptthemen laut MEDLINE: Rifaximin, Epiregulin, Liver Cirrhosis, Interleukin-8. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Metabolic dysfunction-associated steatohepatitis (MASH) is a progressive liver disease linked to fibrosis and hepatocellular carcinoma (HCC). Gut-derived lipopolysaccharide (LPS) promotes hepatic inflammation, fibrosis, and angiogenesis through toll-like receptor 4 (TLR4) signaling. This study examined the effects of rifaximin, a non-absorbable, gut-targeted antibiotic, on MASH-related liver fibrosis and early hepatocarcinogenesis, with a focus on the LPS–epiregulin–IL-8–angiogenesis axis.MASH was induced in Fischer 344 rats using a choline-deficient, L-amino acid-defined high-fat diet (CDAHFD). Rifaximin (30 mg/kg/day) was orally administered for 12 weeks. Liver histology, gene expression, intestinal permeability, LPS levels, and angiogenic markers were evaluated. Rifaximin reduced hepatic inflammation, fibrosis, hydroxyproline content, and fibrogenic gene expression. The number and size of GST-P-positive preneoplastic lesions and proliferation-related genes were decreased. Portal LPS levels and Kupffer cell activation declined, with downregulation of Lbp, Cd14, Tlr4, and inflammatory cytokines. Rifaximin decreased hepatic epiregulin and IL-8 expression, attenuated CD34-positive neovascularization, and suppressed proangiogenic gene expression, accompanied by improved intestinal barrier function and reduced gut permeability. Rifaximin mitigates MASH progression by restoring gut barrier integrity, limiting LPS translocation, and inhibiting fibrogenic and angiogenic pathways. These results suggest its potential as a chemopreventive agent in MASH-related hepatocarcinogenesis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Gastroenterology, Nara Medical University, Kashihara 634-8521, Nara, Japan.
- Medical Affairs Department, ASKA Pharmaceutical Co., Ltd., Minato-ku 108-8532, Tokyo, Japan.
ORCID-Profile: Norihisa Nishimura, Koh Kitagawa, Shinya Sato, Tadashi Namisaki
Zitieren
APA
Nishimura, N., Kaji, K., Nishimura, N., Hanatani, J., Nakatani, T., Oyama, M., Shibamoto, A., Tsuji, Y., Kitagawa, K., Sato, S., Namisaki, T., Tamaoki, S., & Yoshiji, H. (2025). Rifaximin Attenuates Liver Fibrosis and Hepatocarcinogenesis in a Rat MASH Model by Suppressing the Gut–Liver Axis and Epiregulin–IL-8-Associated Angiogenesis. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms26146710
Vancouver
Nishimura N, Kaji K, Nishimura N, Hanatani J, Nakatani T, Oyama M, et al. Rifaximin Attenuates Liver Fibrosis and Hepatocarcinogenesis in a Rat MASH Model by Suppressing the Gut–Liver Axis and Epiregulin–IL-8-Associated Angiogenesis. International Journal of Molecular Sciences. 2025. doi:10.3390/ijms26146710
BibTeX
@article{Nishimura2025,
author = {Nishimura, Naoki and Kaji, Kosuke and Nishimura, Norihisa and Hanatani, Junichi and Nakatani, Tatsuya and Oyama, Masafumi and Shibamoto, Akihiko and Tsuji, Yuki and Kitagawa, Koh and Sato, Shinya and Namisaki, Tadashi and Tamaoki, Satoru and Yoshiji, Hitoshi},
title = {Rifaximin Attenuates Liver Fibrosis and Hepatocarcinogenesis in a Rat MASH Model by Suppressing the Gut–Liver Axis and Epiregulin–IL-8-Associated Angiogenesis},
journal = {International Journal of Molecular Sciences},
year = {2025},
doi = {10.3390/ijms26146710}
}
EUVIMED